Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Durham, North Carolina 27710


Purpose:

The research purpose is to determine if thymus transplantation with immunosuppression is a safe and effective treatment for complete DiGeorge anomaly. The research includes studies to evaluate whether thymus transplantation results in complete DiGeorge anomaly subjects developing a normal immune system.


Study summary:

DiGeorge anomaly is a complex of cardiac defects, parathyroid deficiency, and thymus absence, resulting in profound T-cell deficiency. There is a spectrum of disease in DiGeorge anomaly with respect to all three defects. For complete DiGeorge anomaly subjects with severe T cell defect, the PI had shown that thymus transplantation is safe and efficacious without pretransplantation immunosuppression and with pretransplantation Thymoglobulin and cyclosporine. Some DiGeorge patients have very poor T cell function and are at risk of death from infection or other immune problems; however, these patients have enough T cell function to reject grafts. This protocol was designed for these patients. Atypical phenotype and some typical phenotype DiGeorge subjects were included in this protocol. Atypical complete DiGeorge anomaly patients have rash, lymphadenopathy, and oligoclonal T cell proliferations. The T cells have no markers of thymic function (they do not co-express CD45RA and CD62L; they do not contain T cell receptor rearrangement excision circles, TRECs). Typical complete DiGeorge anomaly patients in this protocol are those whose PHA response >20 fold. Although these patients have very low T cell function, it may be enough to reject a transplant, so Thymoglobulin was used.


Criteria:

Transplant Inclusion - No age limit - Thyroid studies must be done and if abnormal, must be on therapy DiGeorge diagnosis - must have 1 symptom from the following list: - Heart defect - Hypocalcemia requiring replacement - 22q11 hemizygosity - 10p13 hemizygosity - CHARGE association - Abnormal ears plus mother with diabetes (type I, type II, or gestational) Atypical Diagnosis: - Must have, or have had, a rash. If rash present, biopsy of rash must show T cells in skin. If rash & adenopathy resolved, must still have oligoclonal T cells. - Within 1 month of tx must have PHA response >20 fold above background or >5,000 cpm, whichever is higher, or response can be < this. - Circulating CD3+ T cells >50/mm3 but CD45RA+CD62L+CD3+ T cells <50/mm or <5% of CD3 count, whichever is higher (must be done 2x) - Immunoscope with >40% oligoclonal TCRBV families. A 2nd test per sponsor discretion if T cell numbers increase or activation status changes. - If TREC done pre-tx must have TRECs <100 per 100,000 CD3+ cells. Typical Diagnosis: - Circulating CD3+ CD45RA+ CD62L+ T cells and <50/mm3 or <5% of total T cells - PHA response >20 fold above background or >5,000 cpm, whichever is higher. - 2 studies must show similar immunological findings qualify for this study. - TRECs, if done, should be <100/100,000 CD3 cells Transplant Exclusion: - Heart surgery <4 weeks pre-tx date - Heart surgery anticipated w/in 3 months of proposed tx - Rejection by surgeon or anesthesiologist as surgical candidates - Lack of sufficient muscle tissue to accept 0.2 grams/kg transplant


NCT ID:

NCT00579709


Primary Contact:

Principal Investigator
M. Louise Markert, MD, PhD
Duke University Medical Center, Pediatrics, Allergy & Immunology


Backup Contact:

N/A


Location Contact:

Durham, North Carolina 27710
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: June 25, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.